The Efficiency, Predictability, and Safety of First-Generation (Visumax 500) and Second-Generation (Visumax 800) Keratorefractive Lenticule Extraction Surgeries: Real-World Experiences

被引:2
|
作者
Lee, Chia-Yi [1 ,2 ,3 ]
Lian, Ie-Bin [4 ]
Chen, Hung-Chi [5 ,6 ,7 ]
Huang, Chin-Te [8 ,9 ]
Huang, Jing-Yang [10 ]
Yang, Shun-Fa [1 ,10 ]
Chang, Chao-Kai [2 ,11 ]
机构
[1] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan
[2] Nobel Eye Inst, Taipei 115, Taiwan
[3] Jen Ai Hosp Dali Branch, Dept Ophthalmol, Taichung 402, Taiwan
[4] Natl Changhua Univ Educ, Inst Stat & Informat Sci, Changhua 500, Taiwan
[5] Chang Gung Mem Hosp, Dept Ophthalmol, Linkou 333, Taiwan
[6] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou 333, Taiwan
[7] Chang Gung Univ, Coll Med, Dept Med, Taoyuan 333, Taiwan
[8] Chung Shan Med Univ Hosp, Dept Ophthalmol, Taichung 402, Taiwan
[9] Chung Shan Med Univ, Sch Med, Dept Ophthalmol, Taichung 402, Taiwan
[10] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan
[11] Da Yeh Univ, Dept Optometry, Chunghua 515, Taiwan
来源
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词
keratorefractive lenticule extraction; visumax; 800; smile pro; uncorrected distance visual acuity; spherical equivalent; CLINICAL-OUTCOMES; SMILE; ASTIGMATISM; LASIK; MYOPIA;
D O I
10.3390/life14070804
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We aimed to evaluate the postoperative visual and refractive outcomes between the first- and second-generation keratorefractive lenticule extraction (KLEx) surgeries. A retrospective cohort study was conducted and patients who had received first- and second-generation KLEx surgeries were enrolled. A total of 80 and 80 eyes were categorized into the first and second KLEx groups after exclusion, respectively. The primary outcomes were the postoperative uncorrected distance visual acuity (UDVA), spherical equivalent (SE), and safety indexes. An independent t-test and generalized estimate equation were implemented to compare the primary outcomes between the two groups. After the KLEx surgery, the UDVA showed no significant difference between the two groups throughout the study period (all p > 0.05), and the postoperative SE and safety index were also statistically identical between the two groups during the follow-up interval (all p > 0.05). There was a similar trend of visual recovery between the two groups (aOR: 0.967; 95% CI: 0.892-1.143; p = 0.844), while the amplitude of the SE change was significantly lower in the second KLEx group (aOR: 0.760; 95% CI: 0.615-0.837; p = 0.005). Nine and two unintended initial dissection of the posterior plane (UIDPP) occurred intraoperatively in the first and second KLEx groups, respectively, and the second group showed a lower risk of UIDPP (p = 0.032). In conclusion, the efficiency, predictability, and safety are similar between first- and second-generation KLEx surgeries.
引用
收藏
页数:10
相关论文
共 30 条
  • [21] Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
    Wright, Eugene
    Gill, Jasvinder
    Huse, Samuel
    Li, Xuan
    Reid, Timothy
    Zhou, Fang L.
    DIABETES, 2021, 70
  • [22] Stent Thrombosis With Second-Versus First-Generation Drug-Eluting Stents in Real-World Percutaneous Coronary Intervention: Analysis of 3806 Consecutive Procedures From a Large-Volume Single-Center Prospective Registry
    Dores, Helder
    Raposo, Luis
    Teles, Rui Campante
    Machado, Carina
    Leal, Silvio
    Goncalves, Pedro Araujo
    Gabriel, Henrique Mesquita
    Almeida, Manuel Sousa
    Mendes, Miguel
    JOURNAL OF INVASIVE CARDIOLOGY, 2013, 25 (07): : 330 - 336
  • [23] Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study
    Ng, Wei-Wei
    Lin, Chen-Chun
    Cheng, Ching-Yuan
    Jiang, Jiunn-Song
    Kao, Shang-Jyh
    Yeh, Diana Yuwung
    PLOS ONE, 2021, 16 (06):
  • [24] Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D plus cohort study
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang Liz
    Bosnyak, Zsolt
    Preblick, Ronald
    Westerbacka, Jukka
    Gupta, Rishab A.
    Blonde, Lawrence
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2148 - 2158
  • [25] Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries
    Park, Kyung Woo
    Lee, Joo Myung
    Kang, Si-Hyuck
    Ahn, Hyo-Suk
    Yang, Han-Mo
    Lee, Hae-Young
    Kang, Hyun-Jae
    Koo, Bon-Kwon
    Cho, Janghyun
    Gwon, Hyeon-Cheol
    Lee, Sung Yoon
    Chae, In-Ho
    Youn, Tae-Jin
    Chae, Jei Keon
    Han, Kyoo-Rok
    Yu, Cheol Woong
    Kim, Hyo-Soo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (05) : 536 - 544
  • [26] Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
    Turnsek, Nina
    Devjak, Rok
    Edelbaher, Natalija
    Osrajnik, Ilonka
    Unk, Mojca
    Vidovic, Dusanka
    Jeric, Tina
    Janzic, Urska
    RADIOLOGY AND ONCOLOGY, 2022, 56 (03) : 371 - 379
  • [27] Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
    Shah, R.
    Girard, N.
    Nagar, S. P.
    Griesinger, F.
    Roeper, J.
    Davis, K.
    Bakker, N.
    Thakrar, B.
    Taylor, A.
    Feliciano, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study
    Mountzios, Giannis
    Koumarianou, Anna
    Bokas, Alexandros
    Mavroudis, Dimitrios
    Samantas, Epaminondas
    Fergadis, Evangelos Georgios
    Linardou, Helena
    Katsaounis, Panagiotis
    Athanasiadis, Elias
    Karamouzis, Michalis, V
    Pentheroudakis, George
    Lampaki, Sofia
    Froudarakis, Marios E.
    Perdikouri, Eleni-Isidora A.
    Somarakis, Alvertos
    Papageorgiou, Foteini
    Paparepa, Zoe
    Nikolaou, Aristeidis
    Syrigos, Konstantinos N.
    CANCERS, 2021, 13 (13)
  • [29] Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
    Hirotsugu Uemura
    Naoya Masumori
    Shunji Takahashi
    Makoto Hosono
    Seigo Kinuya
    Toshiyuki Sunaya
    Tomoyo Horio
    Yutaka Okayama
    Yoshiyuki Kakehi
    International Journal of Clinical Oncology, 2021, 26 : 753 - 763
  • [30] Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
    Uemura, Hirotsugu
    Masumori, Naoya
    Takahashi, Shunji
    Hosono, Makoto
    Kinuya, Seigo
    Sunaya, Toshiyuki
    Horio, Tomoyo
    Okayama, Yutaka
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 753 - 763